Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
26.68
-0.50 (-1.84%)
Oct 1, 2026, 3:56 PM EDT - Market open
Maze Therapeutics Employees
Maze Therapeutics had 141 employees as of December 31, 2025. The number of employees increased by 16 or 12.80% compared to the previous year.
Employees
141
Change (1Y)
16
Growth (1Y)
12.80%
Revenue / Employee
$141,844
Profits / Employee
-$947,447
Market Cap
1.48B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 141 | 16 | 12.80% |
| Dec 31, 2024 | 125 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Ascentage Pharma Group International | 828 |
| Innoviva | 159 |
| Inhibrx Biosciences | 110 |
| AnaptysBio | 104 |
| Tyra Biosciences | 87 |
| ArriVent BioPharma | 77 |
| Korsana Biosciences | 19 |
MAZE News
- 8 days ago - Maze Therapeutics initiated with a Buy at Citi - TheFly
- 9 days ago - Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech - Barrons
- 16 days ago - Maze Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 21 days ago - Maze Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 22 days ago - Maze Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 4 weeks ago - Maze Therapeutics to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Maze Therapeutics Announces Appointments to Its Board of Directors - GlobeNewsWire
- 7 weeks ago - Maze Therapeutics reports Q2 EPS (76c), consensus (70c) - TheFly